Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort

INTRODUCTION: Dolutegravir (DTG)-based antiretroviral therapy (ART) is currently the first-line treatment for people living with HIV. Neuropsychiatric adverse events (NP-AEs) have been reported with DTG but neuropsychiatric symptoms have not been systemically quantified using structured scales. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Phillip, Goh, Orlanda, Kroon, Eugène, Colby, Donn, Sacdalan, Carlo, Pinyakorn, Suteeraporn, Prueksakaew, Peeriya, Reiss, Peter, Ananworanich, Jintanat, Valcour, Victor, Spudich, Serena, Paul, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945418/
https://www.ncbi.nlm.nih.gov/pubmed/31907064
http://dx.doi.org/10.1186/s12981-019-0257-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945418/
https://www.ncbi.nlm.nih.gov/pubmed/31907064
http://dx.doi.org/10.1186/s12981-019-0257-8

Ejemplares similares